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women (1.5% of the population). Women were more likely to have a positive 
initial stress test, 19% versus 12% of men (p < 0.05). 
For utilization (prevalence), the age adjusted rates were mmkedly higher 
for men (2081 per 100,000) than for women (726 per 100,000) and the age- 
adjusted rate ratio was 2.9. The utilization rates pe~ed at ages 60-69 for 
both genders with a rate ratio of 2.5. 
These population-based ata show that, when they have an first stress 
test, women are older, have worse baseline characteristics and are more 
likely to have a positive test. In addition, the utilization of stress testing is 
lower in women. Whether these obsen~etions can solely be attributed to 
differences in disease prevalence remains uncertain particulady for older 
age groups and needs further studies. 
9"8"2--~1 Influence of A Critical Pathway to Maximize Same 
Day Sheath Pulling on An Intsrventional Cardiology 
Ser~']cc: !replications for Length of Stay and 
Complicatio~$ 
Eva Kline, David W. Muller, Stevan W. Warns, Mauro Moscucci, Dean 
J. Karavite, Eric R. Bates, Kim A. Eagle. University of Michigan Heart Care 
Program, Ann Arbor, MI 
In order to evaluate the impact of a critical pathway on process of care 
and outcomes following percutanecus comcaP/interventions, we studied 
257 patients (PTS) undergoing balloon PTCA, coronary atherecfomy, and 
corena~y slant placement (and combinations) from January 1 through June 
30, 1994. The critical pathway case coordinator identified potential candi- 
dates for same-day sheath pull, provided feedback to faculty and fellows 
regarding pathway variances, and tracked bleeding (BLEED) complications 
(hemetoma, need for transfusion or retroperitoneal bfesd) prospectively. 
Study period was divided into three separate two-month blocks. Outcomes 
were assessed for each period and included % of patients having same day 
sheath pull, eligible but not having same day pull, discharged within 48 hours 
(LOS < 48 hrs), and % of PTS having BLEED. The % of PTS having same 
day sheath pull was 41%, 51%, and 51% for the 3 pedods, wh,e the % of 
PT$ eligible but not having same day pull Vended downward from 28% to 
16.6%, to 18.5% (P = N$). 
Jan-Feb Mar-Apr June-July P-Value 
(n=83) (n = 102) (n=S2) 
% PTS LOS < 48 hrs 54% 62% 70% P = 0.04 
% PTS BLEED 26% 14.7% 11.9% P = 0.02 
Conclusion: Use of a critical pathway to monitor complications and maxi- 
mize same day sheath pull for short stay PTCA patients was associated with 
a higher % of early discharge and lowering of bleeding complications. Over- 
all mortality, MI, and repeat anglography were infrequent and comparable 
during the study periods. 
~ ' ~  Predlcters o f  Early Discharge After Cardiac Surgery 
and Its Cost-Effect iveness 
Nancy J. Nickerson, Susan R Murphy, Nicholas T, Kouchoukos, Bill B. Daily, 
Kenneth B. Schechtman, Victor G. D~vila-Rom~n. Washington University 
School of Medidneo St. Louis, MO 
There are limited data on the predictors and cost-effectiveness of decreasing 
postoperative length of stay (LOS) after cardiac surgery. We evaluated an 
Early Discharge lED) protocol that consisted of modifying anesthesia, limiting 
the use of postoperative narcotics, esdy extubaUon and mob,lzation, and 
hospital discharge at < 5 days. ED criteria included hemodynamlc stability, 
nomlai bowel function, independence in activities of daily living, and the 
absence of fever and incisionai problems. This approach was prospectively 
applied In 422 consecutive patients (age range 15-89 years, 65%0 men): 
CABG (n ,= 290), valve procedures (n ,, 54), or CABG + valve pmcadures (n 
,, 78). Early extubation (_< 10 hrs) was achieved in 43%, and 47% had ICU 
stay < 24 hours. ED was achieved in 33% of the entire group. Predictors of 
Early vs Late Dischargo (muifivariete analysis): 
<_. 5 days > 5 days p value 
Increasing age (years) 61.3 66.8 0.016 
Left venfficulsr dysfunclion* 8,4 9.6 0.02 
CABG + valve (%) 6.5 24.3 0.005 
Female gender (%) 21.7 41.5 0.0006 
Atrial fibrillation (%) 13.0 32.4 0.001 
*CASS left ventricular wall motion score 
The 30 day mortality for the entire group was 3,2%. The 30 day readmisslon 
rate for the ED group was 7.8% vs 16,2% for the late discharge group (p = 
0.01). To assess the cost-effectiveness of this approach, DRGs 106 & 107 
were compared for the 1st quarter of the year ED was implemented (1995) 
and the 1st quarter of the previous year (lgg4). There was an overall cost- 
reduction of $4,500/pt and $1,400/pt, and a decrease in LOS of 2,5 and 1.0 
days, respectively. Thus, decreased postoperative LOS can be accomplished 
safely in the cardiac surgical population and is associated with d~..mased 
cost. 
~-]  Implantable Cerdioverter-Defibrillators 
Tuesday, March 26, 1996, 3:00 p.m.--5:00 p.m. 
Orange County Convention Center, Hall E 
Presentation Hour: 4:00 p,m.-5:00 p.m. 
9~-~'1  Long-Term Performance of Pace-Sense Lead 
Systems for Implantsble Cardioverters 
Linette Ktsvan, Ma;'tha Tenzer, Robert Bemstein, Lenox Baker, 
Szabolcs Szentpetery, Jeffrey Rich, John M. Herre. Eastern Virginia Medical 
School, SanPara Norfolk General Hospital, Norfolk, VA 
With increasing sophistication of Imptantable cardioverter detibrilletore (ICDs), 
long term intngdty of the sense-pace lead system has become more impor- 
tant. We evaluated pace-sense lead systems in 457 patients (pts). Paca- 
sense lead systems were replaced for oversenaing, lead fracture, failure to 
detect or redetect ventdcular f~rilletlon and inability to pace. Pace-sense 
lead systems were replaced aiectivety at time of pulse generator (PG) m- 
placement if R < 3.0 mV or pacing threshold • 2.5 V. Pts were 77.5% male, 
ages 16 to 90. Ejection fraction was 0.34 ± 0.15 (mean ~ S.D.) and 62.6% 
o! pts had CAD. 
n Months 
6 12 24 38 48 
Pace-sense lead survival 
Pace-sense-defibdllate 
CPI Endotak 231 0.97 0.97 0.85 0.88 0.81 
Medlronic Transvene 39 1.0 1.0 + + + 
Ventritex TVL 14 1 .O 1.0 + + + 
Bipolar t'ransvenous pace-sense 67 0.97 0.95 0.89 0.82 0.76 
Eplcerdial screw-in pace-sense 106 1.0 1.0 0.91 0.82 0.71 
Overallptsurvival 457 0.94 0.92 0.87 0.83 0.79 
+Insufficient data 
Conclusions: Pace-sense lead problems can be expected in 20-30% of 
ICD pts at 4 years with a vend toward better long-term performance with 
tTansvenous pace-sense-defibrillete l ads. Replacement of epicerdiai paca- 
sense leads should be considered at PG replacement. 
J '~ ' -3"~ Defibri l lation Eff icacy o f  Dif ferent Defibri l lator 
Case Sizes In Patients: How Smal l  Is Too Small? 
Andrea Nataie, Margaret M. Keamey, M. Joan Brandon, Virgini~ Kent, 
Eric Fain, Keith H. New'oy. VA Medical Canter~Duke University, Durham, NC 
The use of prophylactic cardtoverter-defibd,ator implantation could be lim- 
ited by the size of current devices. The single lead unlpolar system could 
represent on attractive technology for this use if a small size can maintains a 
deflbd,ation efflcaw similar to larger sizes. We tested the defibdllation suc- 
cess of a 73 co, 40 co, and 16 co defibrillator cans in 10 consecutive patients 
undergoing defibrillator implant. In each patient, all 3 sizes were tested in 
randomized order. Blphasic shocks were delivered using the external defib- 
rillator HV$/O2. The mean energy (joules) and peak voltage at defibrillation 
threshold are shown: 
73cc 40cc 16c¢ 
Energy 12.5 -4- 4.3 12.9 ± B.0 13.2 • 5.8 
Vol!age 441 ±803 445~ 110 451 ±94 
p = NS for all comparisons 
Conclusions: even a can volume of 16 cc does not affect he defibrillation 
efficacy of the single lead unlpolar system. A defibrillator of this size will 
certainly be more acceptable for prophylactic use and appears to be feasible. 
Autonomic Nervous Dysfunction in Patients With 
Implanted Defibrillator 
Christeph Ehlere, Dietrich A~lresen, Bettina Wiederkehr, 
Thomas Br0ggemann, Wolfgang Ziss, Heinz-R Schutthai8. Dpt. Cardiology, 
Benjamin Frank~in Medical Center, Free University of Bedin, Germany 
Nonlnvasive cardiovascular reflex tests, performed to assess for cardiac 
autonomic nervous dysfunction, have shown to predict clinical outcome in 
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patisn~ following myocardial infarction. However, little is known about the 
prognostic value of these tests in patients with malignant ventdcular tach- 
ya#nythmias. 
Method: The deep breath test (DB) is a widely used cardiovascular reflex 
test. It measures the difiemcoe (Diff) between maximum head rate dudng 
deep inspiration and minimum heart rate during deep expiration, The test 
is nontnvaslve, straight forward and easy to perform, 36 pts (34 male, 2 
female, mean age: 52 4-12 yrs}, who had been resuscitated from ventdcular 
fibrillation underwent DB before implantation of a cardioverterldef~dllalor 
(iCD). 
Resu~: The mean heart rata dudng the pretest pedod was 75 4- 13 
beata/mlo.. Dudng deep inspiration mean heart rate increased to 84 ± 13 
beete/min and decreased after expiration to 67 4- 12 beats/rain (p = 0.001). 
18/36 (50%) lots had an abnormal DB (Diff > 15 beats/min) (group A), the 
remaining 18 demonstrated a normal test (group B). Group A and B were 
comparable with respect o ag,~, qender, underlying heart disease (CHD: 68 
vs 68%), ejection fraction (42 v-~ ,k3%), NYHA-class (class III 22 vs 27%), 
induciimTdy dudng programmed stimulation (48 vs. 54%). 
During a mean follow up of 14 4- 4 months 20/36 (56"/,) pts developed 
apprepdate shocks, 16 (89=/=) lOtS in group A, but only 4 (22°/,) lots in group B 
(p =, 0.001 ). 
Conclusion: The DB is appropriate for assessing cardiac autonomic ner- 
veus dysfunction in ICD-pattants. An abnormal DB predicts an unfavorable 
clinical outcome and indicates pecific trigger mechanisms for subsequent 
arrhythmic events. 
~ Long-TemlStabil ity the Defibrillation Threshold of  
With A Pectoral Unipelar Defibrillation System 
Wemer Jung, Christian Wolpert, Burkhard H0gl, Thomas Kode, 
Christian Schneider 1, Bahman Esmailzadeh ~, Dietrich Pfe'~er, 
J0rgan Tebpenjohanos, Susanne Spohl, Bemdt LQderitz. University of 
Bonn, Bonn, Germany; 1 Depts. of Cardiology and Cardiovascular Surge#y, 
Bonn, Germany 
The chronic stability of the detibdllation threshold (DFT) in patients (pts) with 
an aCtive pectoral defibrillation system remains still to be defined. We report 
on our experience with a single lead unipolar pectoral defibrillation system in 
52 consecutive pta dudng a follow-up eriod of 12 months. The defibrillation 
lead system consisted of a single transvenous dght ventdcular electrode 
(cathode) and the shell (anode) of an active, left poctorally implanted efibril- 
lator device (Medtronio, model 7219 C). DFT was determined in all pts using 
a binary search protocol at th~ time of implant, at ¢lischmge, after 3, 6, and 
12 months. 
Stored energy [J] Resistance [Ohm] 
At Implant: 9.8 4. 6.3 53 4. 5 
At predlscharge: 7A :t: 4.9 47 4. 6 
At 3 month: 8.34-5.9 564-6 
At 6 month: 7.9±6.1 594-7 
At I~ month: 8.8 4. 6.8 60 .~- 6 
Intmoperetively, the defibrillation success rate at 9 J, 12 J, 18 J, and 
24 d was 58%, 83%, 90%, and 98%, respectively. There was no significant 
change in stored energy atthe DFTforthe total patient population dudng a 12 
month follow-up pedod. Furthemlore, a significant dse In defibrillation energy 
requirements did not occur In a single patient throughout the observation 
paflod. 
Conclusior~e: Defibrillation thresholds remain stable over a 12 month fotiow- 
up podnd using the unipolar pectoral datibnllation lead system. This obser- 
vation has important clinical implications for future Implantable cardioverter- 
defibrillators with reduced energy outputs to ensure an adequate enet~gy 
safety margin for continued effectiveness. 
Reduced Defibrillation Thresholds With 
Endooardlal Administration of Artllide 
$. Adam Stddd~rger, Vinod Labhasetwar, James Davis, 
Thomas Undatwoed, Robert J. Levy. University of Michigan, Ann Arbor, 
Mk~higan 
A daflbdllatton energy requirement (DER) with adequate safety margins is 
required for Implantation ofa datibdllator. Many patients require antiarrhyth- 
ml¢ (AA) drugs to decrease the frequency of ICD therapies, and these drugs 
may elevate the DER. Therefore, the purpose of this study was to determine 
the effect of local endocardlal delivery of artilide, a type III AA, on the DER 
of dogs. In 11 dogs, the chest wa.~ opened and two eptcardlal defibrillation 
patches (CPI model 1.67) were placed. DER datamdnations used an up- 
down protocol. The likelihood of 50% (ED 50) and 100% (ED 100) successful 
dal!lbdllation were calculated. Five minutes were allowed to elapse between 
each Induction of ventdcular flbdllation. A transvenous lead (TVL; CPI model 
0060) with a controlled release drug delivery system attached to tha tip was 
then placed transvenously Into the apex of the right ventricle. In 6 dogs the 
deliver/system was impregnated wiat 20% artilide, and in 5 dogs no drug 
(control) was putinto the system. Thirty minutes later, the DER was deter- 
mined again. Before the TVL was positioned, the ED 50 and ED 100 were 
8.6 4- 2.7 J and 14.0 4- 2.2 J in the control animals, and 8.0 4- 2.0 J {p = 
NS ve control) and 13.3 4- 4.1 J (p = NS vs control) In the dogs tr~'~ted with 
the artillde, respectively. After positioning the TVL, the artifide ED 50 and 
ED 100 decreased to 4.8 4- 0.9 J (p = 0.0005) and 8.5 4- 3.7 J (p = 0.02), 
respectively. For the control dogs, the ED 50 and the ED 100 did not change 
significantly (6,2 4- 2.4,1, 13.0 4- 2.7J, respectively). In conclusion, artilide 
appears to decrease the acute ED 50 and ED 100 in dogs. This effect can 
be achieved with the endocar~al administration ofthis agent via a contmlisd 
release system that results in low systemic oncontmtians. 
I "~-~- - I  1"lining of the Upper Limit of Vulnerebility Is 
Different for Monophasic and Biphasic Shocks: 
Implications for  the Relation to the Defibrillation 
Threshold 
Steffen Behrens, Cuiisn Li, Michael R. Franz. Georgetown University and 
VA Medical Center, Washington, DC 
Background and Methods. The upper limit of vulnerability (ULV) has been 
used in clinical studies to predict he det~dllallon threshold (DFT) in patients 
with implantable delrmillators. Despite the ULV-DFT correlation, uncertainties 
about the optimal timing of the ULV determination remain, To compare the 
precise timing of the ULV for monophasic (Mo) and biphasic (Bi) shocks, 
10 isolated rabbit hearts were immersed in a tissue bath flanked by shock 
electrodes, Mo and Bi T wave shocks (overall duration 5 ms) wero randomly 
delivered uring the vulnerable pedod at shock strengths above and below 
the ULV with a 10 ms resolution for shock coupling intervals. The ULV was 
defined as the highest VF inducing shock strength. 
Resutts. The ULV showed a substantial intra-individual variation with re- 
spect to shock timing and voltage. However, in all hearts the ULV for Bi 
shocks occurred at longer coupling intervals as compared to Mo shocks (186 
4- 9 vs 173 4- 5 ms, p < 0.001). This resulted in a mere complete repolar- 
ization level (RL) at the Bi ULV (81.1 4- 7.5 vs 66.9 4- 9.0% RL, p = 0.502) 
measured by simultaneously recorded monophasic action potentials from 
different eodocardlal nd epicardial sites. As expected, the ULV voltage was 
lower for Bi than for Mo shocks (difference 44 4- 42V, p == 0.012) reflecting 
the higher defibrillation efficacy of the Bi waveform. 
Conc/uslons. The ULV for Bi shocks occurs at a more complete repelar- 
ization state as compared to Mo shocks, thereby resulting in a rightward shift 
of the ULV towards longer coupling intervals. This is important for the deter- 
mination of the ULV-DFT correlation. Our findings also explain why different 
ULV coupling intenrais with respect to the T wavo have been proposed in 
previous tudies. 
~'~- ]  Relationship Between Amiodarone and 
Desmethylamlodarone Levels and Ventdeular 
Deflbdllaflon Energy Requirements 
Emile Daoud, Awais Siddique, K. Ching Man, Laura Horwoed, Fred Momdy, 
S. Adam Stdckbeq]er. University of Michigan Hospital, Ann Arbor, MI. 
Pdor studies have suggested that amiodarens raises defibrillation energy 
requirements (DER), however no studies have assessed the effect of plasma 
concentrations of amiodamne or desmethyl-amiodamne (OF.A) on the DER. 
We prospectively assessed the effect of amiodamne, amledamno levels, 
and DEA levels on the DER. The DER was ~termlnsd with a monophaslc 
weveform with a single transvenous lead system. Intraopet~ DER was 
determined using a step-down protocol: 25, 20,15,10, 5, 3 ano 1J. The DER 
was defined as the minimum energy that converted vantdcular fibnllatlen to 
sinus rhythm. If the DER was > 25,1, the DER was considered elevated and 
was estimated to be 30,1. Prospective data were collected In 102 lots (76 M; 
24 F}. The msan age was 02 4- 13, the moan ejection haction was 0.31 4- 
0.14. There were no ddlemncee between patients mcaiving anliedarane (n 
= 39) vs those not receiving amloderane (n = 62) in age, gender, ejection 
fraction, type of heart disease, prior coronary artery bypass sungery, body 
surface area and left voutficolar internal diastolic dimension and mass. The 
mean duration of amiodarene use was 24 4- 33 days (range: 7-181 days). 
The mean DER was 18 4- 9J. At implantation, the mean andedamne level 
was 0.3 4- 0,6 rag/L, and the mean DEA level was 0.25 4- 0.4 mg/L Pte 
receiving amiodarone had a significantly higher DEll (22 4- 10J vs 17 4- 9J, 
p = 0.01). There was no significant correlation between amiodamn~ level 
(p = 0.4) or DEA level (p = 0.1) and the DER. In conclusion, the use of 
amiederons Is associated with elevated acute DER's, regamlass of plasma 
amiodarone or DEA concentrations, and even when these concentrations 
are subtherapautic, 
